Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

ase contains forward-looking statements, including without limitation statements related to the potential safety and efficacy and commercial potential of voreloxin, the completion of the tranched financing, the activity of voreloxin in nonclinical studies, planned additional enrollment, clinical testing and development efforts, the timing of the End-of-Phase 2 meeting with FDA and the company's ability to transfer to The NASDAQ Capital Market. Words such as "demonstrating," "planning," "promising," "shows" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Sunesis' need for additional funding, the risk that Sunesis' drug development activities could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' nonclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials, including the pace of enrollment, risks related to the manufacturing of voreloxin, the risk that Sunesis' proprietary rights may not adequately protect voreloxin and the risk that NASDAQ does not permit Sunesis to transfer to The NASDAQ Capital Market and that Sunesis may be subject to delisting proceedings. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 and othe
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 “Our nation's healthcare system ... national disgrace. Furthermore, every governmental and professional entity ... deplorable state of unorganized dysfunction shares in that ... merely serve as a device to use in ... failure(s) that have accumulated through the years leading ...
(Date:8/21/2014)... research team including DESY scientists has observed tiny quantum ... reports in the journal Science that the ... the nanodroplets. It is the first time that the ... samples of what is known as superfluid helium, have ... best expectations," says Andrey Vilesov of the University of ...
(Date:8/21/2014)... COLD SPRING, N.Y. , Aug. 21, 2014 ... today the launch of their Nutraceutical "TELO-20 for ... first and only Telomere-lengthening supplement in the world ... the ends of every chromosome in the body. ... the world,s leading experts in Telomere Science and ...
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... part of its ongoing efforts to improve the quality ... diagnosed with scoliosis, Axial Biotech, Inc., a company revolutionizing ... today announced that it has signed a multi-year agreement ... The agreement focuses on providing access to ...
... 2011 ,   Amsterdam ... human gene therapy, today announced the appointment of,Dr. Carlos ... AMT more than 25 years of pharmaceutical industry experience,most ... approvals at the European Medicines Agency (EMA),and U.S. Food ...
... Nottingham and using nanotechnology 100,000 times smaller than the thickness ... the vast energy of the Sun to produce clean fuel. ... Society,s annual Summer Science Exhibition which opens ,today [5 July ... have already found a way to produce hydrogen from water. ...
Cached Biology Technology:Axial Biotech Signs Agreement With Shriners Hospital for Children 2Axial Biotech Signs Agreement With Shriners Hospital for Children 3Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer 2Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer 3Putting sunshine in the tank 2
(Date:8/21/2014)... BOSTON -- Nine researchers from Beth Israel ... included in "The World,s Most Influential Scientific Minds ... from Thomson Reuters ScienceWatch, a web resource for science ... scientists recognized as among the most influential "are performing ... to the advancement of their science," according to a ...
(Date:8/21/2014)... window? It consists of radiations in the 3.3 to ... water in biological tissues. New theoretical findings show that ... water window. These could be the basis of an ... biological samples or to be used in high-precision spectroscopy. ... needed to efficiently generate the harmonic radiationswhich are multiples ...
(Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
Breaking Biology News(10 mins):BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2
... major relief this spring or summer from the unusually dry ... new projections of drought severity and fire risk that are ... The analysis, which was developed by researchers at the U.S.D.A. ... northwestern part of the country will face forest and rangeland ...
... novel bio-bar-code amplification (BCA) technology, researchers analyzing fluid from ... protein linked in recent studies to Alzheimer's disease. , ... : , - Gold nanoparticles and bio-bar codes ... Codes for the Ultrasensitive Detection of Proteins ,- ...
... protects the body's infection-fighting cells might also contribute to ... disease, UT Southwestern Medical Center researchers have found. , ... inhibits cell death in macrophages, which circulate in the ... foreign substances. The AIM-protected macrophages go on to encourage ...
Cached Biology News:No relief for Pacific Northwest drought 2No relief for Pacific Northwest drought 3Nanoscale Diagnostic Sets Sights on Alzheimer's 2Nanoscale Diagnostic Sets Sights on Alzheimer's 3Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries 2
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Hamartin/TSC1 (1B2) Mouse mAb Ship: Hot Store: -20 C...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: